RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Acorda Therapeutics Stock

Acorda Therapeutics Stocks 2025

Acorda Therapeutics Stocks

1.24 M

Ticker

ACOR

ISIN

US00484M6012

WKN

A0BK80

In 2025, Acorda Therapeutics had 1.24 M outstanding stocks, a 0% change from the 1.24 M stocks in the previous year.

The Acorda Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2025e1.24
2024e1.24
20231.24
20221
20210.5
20200.4
20190.4
20180.4
20170.4
20160.4
20150.4
20140.4
20130.3
20120.3
20110.3
20100.3
20090.3
20080.3
20070.2
20060.2
20050.2
20040.2

Acorda Therapeutics shares outstanding

The number of shares was Acorda Therapeutics in 2024 — This indicates how many shares 1.242 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Acorda Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Acorda Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Acorda Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Acorda Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Acorda Therapeutics Aktienanalyse

What does Acorda Therapeutics do?

Acorda Therapeutics Inc. is a US-based biopharmaceutical company that specializes in researching, developing, and marketing therapeutics for severe neurological diseases. The company was founded in 1995 by Ron Cohen and is headquartered in Ardsley, New York. Acorda Therapeutics started as a small company with few employees and one product, Zanaflex Capsules, a muscle relaxant used for spastic conditions. The company expanded its product portfolio through acquisitions, such as the acquisition of Neuronetrix Solutions, Inc., a company specialized in diagnosing Alzheimer's and other cognitive impairments. Acorda Therapeutics has a business model focused on research and development activities and has formed partnerships with industry experts, academic institutions, and healthcare facilities to support its research efforts. The company has a strong focus on neurology and has expertise in developing protein and antibody-based medications for neurological diseases. Acorda Therapeutics' goal is to meet the needs of patients with severe neurological diseases and develop innovative therapeutics that provide real clinical benefits. The company's main products are Ampyra, an oral medication for improving walking ability in patients with multiple sclerosis, and Zanaflex Capsules, used to treat spastic conditions. Acorda Therapeutics has also developed Inbrija, an inhaled levodopa for treating off-episodes in patients with Parkinson's disease. In addition to medications, the company has developed diagnostic and monitoring devices, such as a device for monitoring vagus nerve stimulation in epilepsy patients, in partnership with Medtronic. Acorda Therapeutics has made significant contributions to the treatment of neurological diseases and has a track record of success in developing collaborative therapies and diagnostic products. While there is still much work to be done, there is hope that continued research and development of new and innovative therapeutics can improve the quality of life for millions of people suffering from severe neurological diseases. Acorda Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Acorda Therapeutics's Shares Outstanding

Acorda Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Acorda Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Acorda Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Acorda Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Acorda Therapeutics stock

How many stocks are there of Acorda Therapeutics?

The current number of stocks of Acorda Therapeutics is 1.24 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Acorda Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Acorda Therapeutics evolved in recent years?

The number of shares of Acorda Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Acorda Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Acorda Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Acorda Therapeutics pay?

Over the past 12 months, Acorda Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acorda Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Acorda Therapeutics?

The current dividend yield of Acorda Therapeutics is .

When does Acorda Therapeutics pay dividends?

Acorda Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acorda Therapeutics?

Acorda Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Acorda Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acorda Therapeutics located?

Acorda Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acorda Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acorda Therapeutics from 4/30/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/30/2025.

When did Acorda Therapeutics pay the last dividend?

The last dividend was paid out on 4/30/2025.

What was the dividend of Acorda Therapeutics in the year 2024?

In the year 2024, Acorda Therapeutics distributed 0 USD as dividends.

In which currency does Acorda Therapeutics pay out the dividend?

The dividends of Acorda Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Acorda Therapeutics

Our stock analysis for Acorda Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acorda Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.